Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Log In

    Show
    Forgot your password?
    Log In
    Or create a new account (it's free)

    Forgot Password?

    Enter your email address and we'll send you a link to reset your password.

    Get New Password

    Sign In Required

    To save favorites, you must log in.

    Creating an account is free, easy, and takes about 60 seconds.

    Already have an MDCalc account?

    Login to link your favorites and recently used calcs

    Show
    Forgot your password?
    Log In
    Or continue to Nuance

    Attention COACH STUDY participants:

    The principal investigators of the study request that you use the official version of the modified score here.

    Revised Multiple Myeloma International Staging System (R-ISS)

    Prognostication tool for myeloma patients based on the genetics and other routinely used lab values in conjunction with the original ISS Staging System.

    INSTRUCTIONS

    Use only in patients recently diagnosed with multiple myeloma. Do not use in patients with relapsed myeloma, smoldering myeloma or MGUS.

    When to Use
    Pearls/Pitfalls
    Why Use

    Newly diagnosed MM patients. Its utility has NOT been validated in relapsed myeloma, smoldering myeloma or MGUS patients.

    • The revised International Staging System (R-ISS) for multiple myeloma was developed to better prognosticate long term outcomes of myeloma patients using easily obtained and routinely used prognostic variables.
    • It includes the parameters from the International Staging System (ISS), as well as cytogenetic abnormalities (CA) serum lactate dehydrogenase (LDH).
    • The R-ISS creates 3 subgroups with significantly different overall survival:
      • Stage I: 82%
      • Stage II: 62%
      • Stage III: 40%
    • It risk-stratifies multiple myeloma patients better than the original ISS.
    • 40% of patients in the data set were not transplant eligible, which reflects a more real-world population than does previous studies
    • Provides better discrimination of prognosis for MM by using simple, readily available variables.
    • Reliable, validated tool that may have a role in upfront risk stratification in future clinical trials, and also may help patients understand their prognosis better.
    <3.5 mg/L
    3.5-5.4 mg/L
    >5.4 mg/L
    <3.5 g/dL
    ≥3.5 g/dL
    Standard risk
    High risk
    Normal (< upper limit of normal)
    High (> upper limit of normal)

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Antonio Palumbo

    About the Creator

    Antonio Palumbo is chief of the Myeloma Unit of the Department of Oncology, Section of Hematology at the University of Torino. He is currently a member of the Board of Directors of the International Myeloma Society. Dr. Palumbo's research focuses on plasma cell dyscrasia, and the pathogenesis and treatment of multiple myeloma.

    To view Dr. Antonio Palumbo's publications, visit PubMed

    Are you Dr. Antonio Palumbo? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
    MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.
    Content Contributors
    About the Creator
    Dr. Antonio Palumbo
    Are you Dr. Antonio Palumbo?
    Content Contributors